Novel Therapies for Unmet Clinical Needs in Myelodysplastic Syndromes
- PMID: 36230864
- PMCID: PMC9562187
- DOI: 10.3390/cancers14194941
Novel Therapies for Unmet Clinical Needs in Myelodysplastic Syndromes
Abstract
Myelodysplastic syndromes (MDS) are a very heterogeneous disease, with extremely variable clinical features and outcomes. Current management relies on risk stratification based on IPSS and IPSS-R, which categorizes patients into low (LR-) and high-risk (HR-) MDS. Therapeutic strategies in LR-MDS patients mainly consist of erythropoiesis stimulating agents (ESAs), transfusion support, and luspatercept or lenalidomide for selected patients. Current unmet needs include the limited options available after treatment failure, and the consequent transfusion burden with several hospital admissions and poor quality of life. Therapeutic approaches in HR-MDS patients are aimed at changing the natural course of the disease and hypometylating agents (HMA) are the first choice. The only potentially curative treatment is allogeneic stem cell transplant (allo-HCT), restricted to a minority of young and fit candidates. Patients unfit for or those that relapse after the abovementioned options harbor an adverse prognosis, with limited overall survival and frequent leukemic evolution. Recent advances in genetic mutations and intracellular pathways that are relevant for MDS pathogenesis are improving disease risk stratification and highlighting therapeutic targets addressed by novel agents. Several drugs are under evaluation for LR and HR patients, which differ by their mechanism of action, reported efficacy, and phase of development. This review analyzes the current unmet clinical needs for MDS patients and provides a critical overview of the novel agents under development in this setting.
Keywords: immunotherapy; myelodysplastic syndromes; somatic mutations; target therapy; unmet needs.
Conflict of interest statement
The authors declare no conflict of interest inherent to the present article. BF received consultancy from Apellis, Momenta, and Novartis and lecture fee/congress support from Alexion and Apellis. WB received consultancy from Agios, Alexion, Apellis, Biocryst, Bioverativ, Incyte, Momenta, and Novartis; and lecture fee/congress support from Alexion, Incyte, Novartis, and Sanofi.
Figures

References
-
- Will B., Zhou L., Vogler T.O., Ben-Neriah S., Schinke C., Tamari R., Yu Y., Bhagat T.D., Bhattacharyya S., Barreyro L., et al. Stem and Progenitor Cells in Myelodysplastic Syndromes Show Aberrant Stage-Specific Expansion and Harbor Genetic and Epigenetic Alterations. Blood. 2012;120:2076–2086. doi: 10.1182/blood-2011-12-399683. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous